Advertisement
Surgical Pathology Clinics

Prostate Cancer

Update on Grading and Reporting
  • Ezra Baraban
    Correspondence
    Corresponding author. Department of Pathology, Johns Hopkins Medical Institutions, 401 North Broadway, Weinberg Building, Room 2242, Baltimore, MD 21287, USA
    Affiliations
    Department of Pathology, Johns Hopkins Medical Institutions, 401 North Broadway, Weinberg Building, Room 2242, Baltimore, MD 21287, USA
    Search for articles by this author
  • Jonathan Epstein
    Correspondence
    Corresponding author. Department of Pathology, Johns Hopkins Medical Institutions, 401 North Broadway, Weinberg Building, Room 2242, Baltimore, MD 21287, USA
    Affiliations
    Department of Pathology, Johns Hopkins Medical Institutions, 401 North Broadway, Weinberg Building, Room 2242, Baltimore, MD 21287, USA

    Department of Urology, Johns Hopkins Medical Institutions, 401 North Broadway, Weinberg Building, Room 2242, Baltimore, MD 21287, USA

    Department of Oncology, Johns Hopkins Medical Institutions, 401 North Broadway, Weinberg Building, Room 2242, Baltimore, MD 21287, USA
    Search for articles by this author
Published:October 12, 2022DOI:https://doi.org/10.1016/j.path.2022.07.008

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgical Pathology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Epstein J.I.
        • Zelefsky M.J.
        • Sjoberg D.D.
        • et al.
        A contemporary prostate cancer grading system: a validated alternative to the gleason score.
        Eur Urol. 2016; 69: 428-435
        • Humphrey P.A.
        • Moch H.
        • Cubilla A.L.
        • et al.
        The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours.
        Eur Urol. 2016; 70: 106-119
        • Mohler J.L.
        • Antonarakis E.S.
        • Armstrong A.J.
        • et al.
        Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2019; 17: 479-505
        • Epstein J.I.
        • Amin M.B.
        • Fine S.W.
        • et al.
        The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer.
        Arch Pathol Lab Med. 2021; 145: 461-493
        • Cole A.I.
        • Morgan T.M.
        • Spratt D.E.
        • et al.
        Prognostic value of percent gleason grade 4 at prostate biopsy in predicting prostatectomy pathology and recurrence.
        J Urol. 2016; 196: 405-411
        • Mohler J.L.
        • Antonarakis E.S.
        NCCN guidelines updates: management of prostate cancer.
        J Natl Compr Canc Netw. 2019; 17: 583-586
        • Sadimin E.T.
        • Khani F.
        • Diolombi M.
        • et al.
        Interobserver reproducibility of percent gleason pattern 4 in prostatic adenocarcinoma on prostate biopsies.
        Am J Surg Pathol. 2016; 40: 1686-1692
        • Trpkov K.
        • Zhang J.
        • Chan M.
        • et al.
        Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopathologic findings and disease progression.
        Am J Surg Pathol. 2009; 33: 233-240
        • Baras A.S.
        • Nelson J.B.
        • Han M.
        • et al.
        The effect of limited (tertiary) Gleason pattern 5 on the new prostate cancer grade groups.
        Hum Pathol. 2017; 63: 27-32
        • Wobker S.E.
        • Epstein J.I.
        Differential diagnosis of intraductal lesions of the prostate.
        Am J Surg Pathol. 2016; 40: e67-e82
        • Porter L.H.
        • Lawrence M.G.
        • Ilic D.
        • et al.
        Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories.
        Eur Urol. 2017; 72: 492-495
        • Robinson B.D.
        • Epstein J.I.
        Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings.
        J Urol. 2010; 184: 1328-1333
        • Khani F.
        • Wobker S.E.
        • Hicks J.L.
        • et al.
        Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
        J Pathol. 2019; 249: 79-89
        • Guo C.C.
        • Epstein J.I.
        Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
        Mod Pathol. 2006; 19: 1528-1535
        • Miyai K.
        • Divatia M.K.
        • Shen S.S.
        • et al.
        Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.
        Hum Pathol. 2014; 45: 1572-1581
        • Herawi M.
        • Kahane H.
        • Cavallo C.
        • et al.
        Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled.
        J Urol. 2006; 175: 121-124
        • Shah R.B.
        • Nguyen J.K.
        • Przybycin C.G.
        • et al.
        Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
        Histopathology. 2019; 75: 346-353
        • Osunkoya A.O.
        Mucinous and secondary tumors of the prostate.
        Mod Pathol. 2018; 31: S80-S95
        • Bohman K.D.
        • Osunkoya A.O.
        Mucin-producing tumors and tumor-like lesions involving the prostate: a comprehensive review.
        Adv Anat Pathol. 2012; 19: 374-387
        • Tavora F.
        • Epstein J.I.
        Urothelial carcinoma with abundant myxoid stroma.
        Hum Pathol. 2009; 40: 1391-1398
        • McDonald T.M.
        • Epstein J.I.
        Aberrant GATA3 staining in prostatic adenocarcinoma: a potential diagnostic pitfall.
        Am J Surg Pathol. 2021; 45: 341-346
        • Leite K.R.
        • Mitteldorf C.A.
        • Srougi M.
        • et al.
        Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.
        Ann Diagn Pathol. 2008; 12: 260-266
        • Herawi M.
        • De Marzo A.M.
        • Kristiansen G.
        • et al.
        Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
        Hum Pathol. 2007; 38: 72-78
        • Osunkoya A.O.
        • Nielsen M.E.
        • Epstein J.I.
        Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
        Am J Surg Pathol. 2008; 32: 468-472
        • Epstein J.I.
        • Egevad L.
        • Amin M.B.
        • et al.
        The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system.
        Am J Surg Pathol. 2016; 40: 244-252
        • Baisden B.L.
        • Kahane H.
        • Epstein J.I.
        Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy.
        Am J Surg Pathol. 1999; 23: 918-924
        • Magi-Galluzzi C.
        Prostate cancer: diagnostic criteria and role of immunohistochemistry.
        Mod Pathol. 2018; 31: S12-S21
        • Epstein J.I.
        • Allsbrook Jr., W.C.
        • Amin M.B.
        • et al.
        The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma.
        Am J Surg Pathol. 2005; 29: 1228-1242
        • Zhou M.
        • Li J.
        • Cheng L.
        • et al.
        Diagnosis of "poorly formed glands" gleason pattern 4 prostatic adenocarcinoma on needle biopsy: an interobserver reproducibility study among urologic pathologists with recommendations.
        Am J Surg Pathol. 2015; 39: 1331-1339
        • Epstein J.I.
        • Amin M.B.
        • Beltran H.
        • et al.
        Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
        Am J Surg Pathol. 2014; 38: 756-767
        • Kaur H.
        • Samarska I.
        • Lu J.
        • et al.
        Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
        Prostate. 2020; 80: 1012-1023
        • Nadal R.
        • Schweizer M.
        • Kryvenko O.N.
        • et al.
        Small cell carcinoma of the prostate.
        Nat Rev Urol. 2014; 11: 213-219
        • Tan H.L.
        • Sood A.
        • Rahimi H.A.
        • et al.
        Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
        Clin Cancer Res. 2014; 20 (Epub 2013 Dec 9): 890-903
        • Sanguedolce F.
        • Russo D.
        • Mancini V.
        • et al.
        Morphological and Immunohistochemical biomarkers in distinguishing prostate carcinoma and urothelial carcinoma: a comprehensive review.
        Int J Surg Pathol. 2019; 27: 120-133
        • Chuang A.Y.
        • DeMarzo A.M.
        • Veltri R.W.
        • et al.
        Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
        Am J Surg Pathol. 2007; 31: 1246-1255
        • Chuang A.Y.
        • Epstein J.I.
        Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma.
        Am J Surg Pathol. 2007; 31: 1225-1230
        • Oppenheimer J.R.
        • Kahane H.
        • Epstein J.I.
        Granulomatous prostatitis on needle biopsy.
        Arch Pathol Lab Med. 1997; 121: 724-729
        • Fine S.W.
        • Al-Ahmadie H.A.
        • Chen Y.B.
        • et al.
        Comedonecrosis revisited: strong association with intraductal carcinoma of the prostate.
        Am J Surg Pathol. 2018; 42: 1036-1041
        • Srigley J.R.
        • Delahunt B.
        • Evans A.J.
        Therapy-associated effects in the prostate gland.
        Histopathology. 2012; 60: 153-165
        • Gaudin P.B.
        • Zelefsky M.J.
        • Leibel S.A.
        Histopathological effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues.
        Am J Surg Pathol. 1999; 23: 1021-1031
        • Reuter V.E.
        Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy.
        Urology. 1997; 49: 16-22
        • Magi-Galluzzi C.
        • Sanderson H.
        • Epstein J.I.
        Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: duration of atypia and relation to type of radiotherapy.
        Am J Surg Pathol. 2003; 27: 206-212
        • So J.S.
        • Gordetsky J.
        • Epstein J.I.
        Variant of prostatic adenocarcinoma with Paneth cell-like neuroendocrine differentiation readily misdiagnosed as Gleason pattern 5.
        Hum Pathol. 2014; 45: 2388-2393
        • Salles D.C.
        • Mata D.A.
        • Epstein J.I.
        Significance of Paneth cell-like differentiation in prostatic adenocarcinoma: a retrospective cohort study of 80 cases.
        Hum Pathol. 2020; 102: 7-12
        • Giannico G.A.
        • Ross H.M.
        • Lotan T.
        • et al.
        Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study.
        Am J Surg Pathol. 2013; 37: 1401-1406
        • Tan H.L.
        • Haffner M.C.
        • Esopi D.M.
        • et al.
        Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.
        Mod Pathol. 2015; 28: 446-456
        • Osunkoya A.O.
        • Hansel D.E.
        • Sun X.
        • et al.
        Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
        Am J Surg Pathol. 2008; 32: 461-467